Benzinga | May 25, 2021 07:02AM EDT

EyePoint Pharmaceuticals Announces Completion Of Enrollment Of Phase 1 DAVIO Clinical Trial Of EYP-1901 For Potential Treatment Of Wet AMD

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the completion of patient enrollment of its Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).